louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06977425: Efficacy of Intraoperative Magnesium Sulphate vs Dexmedetomidine on Emergence Agitation in Pediatric Patients
Official title: Efficacy of Intraoperative Magnesium Sulphate vs Dexmedetomidine on Emergence Agitation in Pediatric Patients Under Sevoflurane Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Magnesium Sulphate
Dexmedetomidine
Emergence Agitation
Pediatric Patients
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2025-05-18
Enrollment: 60
Sex: ALL
Minimum age (years): 4
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aimed to compare the effectiveness of intraoperative magnesium sulfate versus dexmedetomidine infusions on emergence agitation that follows anesthesia using sevoflurane immediately and after 30 min in the post-anesthesia care unit (PACU), regarding Pediatric Anesthesia Emergence Delirium Scale (PAED), Richmond agitation sedation scale (RASS), and hemodynamics

Detailed description: Emergence agitation (EA) is a postoperative phenomenon that occurs in children after sevoflurane anesthesia, with an occurrence rate of up to 80%.

Dexmedetomidine acts on α-2 adrenergic receptors, producing sedation and hypnosis with anxiolytic effects, without a clinically significant depressive impact on heart rate, blood pressure, and respiratory rate, complementing an earlier study suggesting the possible effective and safe use of dexmedetomidine as a part of anesthesia care to prevent emergence agitation in children.

Magnesium sulfate also has been reported to decrease the incidence and severity of Emergence agitation and the need for postoperative rescue doses of analgesia in children, and its use was not associated with increased postoperative side effects or delayed recovery.

Eligibility criteria: Inclusion Criteria:

* Age from 4 to 8 years old.
* Both sexes.
* Patients American Society of Anesthesiologists (ASA) Physical Status I to II.
* Duration of surgery: not exceeding two hours

Exclusion Criteria:

* Legal guardian refusal.
* Neurological abnormalities, such as cerebral palsy.
* Any physical and/or developmental challenge.
* Patients on sedatives, anticonvulsants, or any medications that may alter conscious level in children.
* Coexisting renal or cardiovascular diseases.

Primary outcomes:
measure: Pediatric Anesthesia Emergence Delirium Scale
timeFrame: 30 minutes postoperatively
Secondary outcomes:
measure: Richmond agitation sedation scale (RASS)
timeFrame: 30 minutes postoperatively
measure: Heart rate
timeFrame: 30 minutes postoperatively
measure: Blood pressure
timeFrame: 30 minutes postoperatively
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain shams university
Study officials:
References:
Clinical trial NCT05361525: Lipoabdominoplasty With Anatomic Definition Versus Traditional Abdominoplasty
Official title: Lipoabdominoplasty With Anatomic Definition Versus Traditional Abdominoplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Abdomen Enlarged
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-05-04
Enrollment: 60
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A tummy tuck also known as abdominoplasty is a cosmetic surgical procedure to improve the shape and appearance of the abdomen.

Detailed description: Lipoabdominoplasty guarantees a safe combination of abdominoplasty and liposuction while minimizing the risk of ischemic flap complications. This is because of the limited undermining performed and the liposuction adjunct, both of which minimize perforator injury. In the last several years, the integration of anatomic definition through the use of liposuction has further refined the procedure, led to improved results, and increased patient satisfaction. The more natural results of the anatomic abdominal definition is a next step in abdominal contour refinement.

Eligibility criteria: Inclusion Criteria:

* Female patients between 25 to 60 with redundant abdominal wall.
* BMI less than 35.

Exclusion Criteria:

* Patients younger than 25 or older than 60.
* BMI more than 35.
* Hernias and scars interfering with abdominal vascularity.
* Patients smoking or with comorbidities (DM, HTN, ...etc).
* Patients seeking for another pregnancies.
* Any causes that may interfere with general anaesthesia. Refusal for any part of the written conset

Primary outcomes:
measure: Aesthetically
timeFrame: 6 months post op
Secondary outcomes:
measure: complications
timeFrame: up to 2 weeks post operatively
Other outcomes:
Locations:
city: Asyut
country: Egypt
facility: Asyut university hospital
Study officials:
References:
Clinical trial NCT01274325: Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma
Official title: Comparison of Anti-inflammatory Effects of Seroflo 125 Inhaler With Seretide Evohaler(25/125) in Patients With Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: asthma
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2011-01-11
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test hypothesis if Sereflo (ICS/LABA) could reduce airway inflammation in asthmatic patients in the same as Seretide.


Eligibility criteria: Inclusion Criteria:

* Age between 20-80 years
* Patients with asthma diagnosed by according to the American Thoracic Society criteria
* A baseline FEV1 \> or = 50% predicted with a reversibility of FEV1 after therapy with inhaled salbuterol (2.5 mg) of FEV1 12% or with provocative concentration of a methacholine causing a 20% fall in FEV1 (PC20) of \< or = 8 mg/mL
* Prescribed use of inhaled corticosteroids (any brand) for at least 12 weeks prior to study entry
* The daily prescribed dose of inhaled corticosteroids during the last 4 weeks prior to study entry should have been constant and at least 250 μg/day of fluticasone at least 400 μg/day of budesonide at least 500 μg/day of any other beclomethasone
* Be able to provide written informed consent

Exclusion Criteria:

* Any asthma exacerbation or respiratory tract infection affecting asthma within 4 weeks prior to the randomization visit
* Intake of oral, parenteral corticosteroids within 4 weeks and/or depot parenteral corticosteroid within 12 weeks prior to the randomization visits
* Current or previous smoker with a smoking history of \> or = 10 pack years
* Previous randomization of treatment in the present study
* Known or suspected hypersensitivity to study therapy
* Use of any β-blocking agent, including eye-drops
* Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive pill measures

Primary outcomes:
measure: Sputum eosinophils
timeFrame: 4 weeks
Secondary outcomes:
measure: Exhaled nitric oxide
timeFrame: 4 weeks
measure: Asthma control test scores
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Kittipong Maneechotesuwan
state: Bangkok
city: Bangkoknoi
country: Thailand
facility: Division of Respiratory Disease and TB, Siriraj Hospital
state: BKK
Study officials:
affiliation: Siriraj Hospital
name: Kittipong Maneechotesuwan, MD., PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02774525: Concurrent Treatment of Substance Abuse and Child Maltreatment
Official title: Concurrent Treatment of Substance Abuse and Child Maltreatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Substance Use
Child Maltreatment
Keywords: child welfare system
parental substance use problem
child maltreatment
parenting
Lead sponsor: University of South Carolina
Sponsor class: OTHER
First posted: 2016-05-17
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The co-occurrence of child maltreatment and parental substance-use problems is a major public health problem with serious consequences for children, parents, families, and the community at large. The need for effective dual treatment of caregiver substance abuse and child maltreatment is unquestionable, but there is a dearth of controlled treatment outcome studies with substance-using parents who have engaged in child maltreatment. This project examines two evidence-based treatments-Contingency Management for substance-use problems and Pathways Triple P parenting intervention to improve parenting for prevention of child-maltreatment recurrence. These two systematic interventions are being tested in the context of traditional outpatient treatment for substance-use problems.


Eligibility criteria: Inclusion Criteria:

* open child protective services case for child maltreatment
* beginning intensive outpatient treatment for drug or alcohol use problem
* at least one child 2-8 years of age

Exclusion Criteria:

* not primary custodial parent for child 2-8 years of age
* serious mental illness
* residing outside the two participating counties

Primary outcomes:
measure: longest duration of negative urine and breath samples
timeFrame: 13 weeks
measure: recurrence of child maltreatment--child protective services records
timeFrame: 18 months after baseline
Secondary outcomes:
measure: self-reported substance use--Addiction Severity Index-Lite
timeFrame: 4 months after baseline; 12 months after baseline; 18 months after baseline
measure: parent report of child behavior problems--child behavior inventory
timeFrame: 4 months after baseline; 12 months after baseline; 18 months after baseline
measure: self-reported parenting--Parenting Scale; Parenting Practices Interview
timeFrame: 4 months after baseline; 12 months after baseline; 18 months after baseline
Other outcomes:
measure: self-reported quality of life--Quality of Life Inventory
timeFrame: 4 months after baseline; 12 months after baseline; 18 months after baseline
measure: self-reported HIV behavioral risk--HIV Risk Behavior Scale
timeFrame: 4 months after baseline; 12 months after baseline; 18 months after baseline
Locations:
city: Columbia
country: United States
facility: University of South Carolina Parenting & Family Res Center
state: South Carolina
Study officials:
affiliation: University of South Carolina
name: Ron Prinz, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00907725: Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?
Official title: Follow-up With Serum BhCG Simplify Medical Abortion: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Medical Abortion
Keywords: medical abortion
serum BhCG follow-up
ultrasonographic follow-up
follow-up methods
Lead sponsor: Planned Parenthood League of Massachusetts
Sponsor class: OTHER
Collaborators: name: Society of Family Planning
First posted: 2009-05-25
Enrollment: 376
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to evaluate if BhCG testing to determine the completion of medical abortion simplifies the medical abortion protocol. Investigators hypothesize that women randomized to ultrasonographic determination of completion of medical abortion will have MORE follow-up visits/interventions beyond standard protocol than those randomized to medical abortion follow-up with serum BhCG.

The investigators also hope to explore satisfaction with BhCG based follow-up among women seeking medical abortion. Investigators hypothesize that the majority of women who choose to follow-up with serum BhCG will be satisfied with this method of medical abortion follow-up.


Eligibility criteria: Inclusion Criteria:

* Pregnant women undergoing medical abortion
* Proficiency in English
* Working phone and willingness to be contacted by phone
* Agreeing to surveys regarding demographics, follow-up preferences, and satisfaction with chosen follow-up method

Exclusion Criteria:

* Concern for ectopic pregnancy or unable to document intrauterine pregnancy
* Clinical instability or signs of pelvic infection
* Medical conditions that contraindicate medical abortion
* Unwilling or unable to comply with study follow-up procedures
* Being in a situation where receiving phone calls or additional contact with research staff may endanger the privacy or safety of the subject (e.g., situations of domestic violence)
* Inability to give informed consent
* Previous participation in this study

Primary outcomes:
measure: Receipt of any additional intervention or follow-up beyond the one routinely scheduled follow-up ultrasound or follow-up BhCG draw
timeFrame: 4 weeks
Secondary outcomes:
measure: Patient satisfaction with follow-up method
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Planned Parenthood League of Massachusetts
state: Massachusetts
Study officials:
affiliation: Planned Parenthood
name: Principal Investigator
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dayananda I, Maurer R, Fortin J, Goldberg AB. Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: a randomized controlled trial. Obstet Gynecol. 2013 Mar;121(3):607-613. doi: 10.1097/AOG.0b013e3182839fda.
Clinical trial NCT04022525: Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches
Official title: Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-07-17
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Rheumatoid arthritis patients from both sexes with different disease activity status receiving solely leflunomide with or without hydroxychloroquine

Brief summary: The RA patients receiving leflunomide for more than one month, and not receiving other DMARDs (except hydroxychloroquine), will be enrolled to assess their disease activity. Blood samples will be collected for genetic studies and pharmacokinetic assay of the blood levels of the drug and its active metabolite.


Eligibility criteria: Inclusion Criteria:

* Rheumatoid arthritis patients already receiving leflunomide with or without Hydroxychloroquine but without other Disease modifying agents

Exclusion Criteria:

* Those diagnosed with other rheumatic diseases or Rheumatoid patients receiving disease modifying agents other than leflunomide

Primary outcomes:
measure: Detection of single nucleotide polymorphisms associated with response to the drug
timeFrame: one -two years
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University Hospital
Study officials:
References:
Clinical trial NCT06833125: The Prophylactic Effect of Garlic Tablets to Prevent Nosocomial Infections in Intensive Care Unit Patients.
Official title: The Prophylactic Effect of Garlic Tablets to Prevent Nosocomial Infections in Intensive Care Unit Patients.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Nosocomial Infection
Keywords: nosocmial infection
prophylaxis
garlic
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2025-02-18
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: It is a randomized non blinded controlled trial. Eligible patients will be randomly divided into two groups: An intervention group which will receive garlic tablets (Tomex plus 300 mg) two tablets twice daily for 6 days just after ICU admission and a control group which will not receive the garlic tablets.
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to learn if garlic tablets works to prevent nosocomial infections in hospitalized patients in ICU. The main questions it aims to answer are:

Does garlic tablets administration lower the occurence of nosocomial infections in hospitalized patients in ICU?


Eligibility criteria: Inclusion Criteria:

* All patients aged from 18 to 65 years old admitted to intensive care units without any type of infection.

Exclusion Criteria:

1. Patients with signs /symptoms of infection.
2. Patients with human immunodeficiency virus, malignancy and patients with a history of recent immunosuppressants or corticosteroids administration.
3. Patients with bleeding disorders or abnormal coagulation profile
4. Patients who will planned for surgery within 2 weeks.

Primary outcomes:
measure: Occurrence of central line-associated bloodstream infections, catheter- associated urinary tract infections, surgical site infections and ventilator- associated pneumonia in the two groups (by cultures results).
timeFrame: one year
Secondary outcomes:
measure: Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups .
timeFrame: one year
measure: Values of Blood white cell count, body temperature and C-reactive protein of the patient in the two groups .
timeFrame: one year
Other outcomes:
measure: Antibiotics consumption as total number of vials per each antibiotic in the two groups.
timeFrame: one year
measure: Lenghth of stay of patients in ICU (by average number of days) in the two groups
timeFrame: one year
measure: Mortality rate of patients in the two groups
timeFrame: one year
Locations:
city: Alexandria
country: Egypt
facility: Alexandria Main University Hospital
Study officials:
References:
Clinical trial NCT01624025: A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Metastatic Advanced Gastric Cancer
Keywords: AGC, second-line, docetaxel, epirubicin
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2012-06-20
Enrollment: 22
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A salvage treatment with combination of docetaxel and epirubicin in patients with unresectable, metastatic gastric cancer after fluoropyrimidine failure : A HER2 status-based study


Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed metastatic, or recurrent AGC
2. Previous use of fluoropyrimidine as palliative chemotherapy. Concurrent use of platinum is permitted. Patient with recurred disease within 6 months after the end of adjuvant therapy can participate to this trial.
3. Documented HER2 expression status.
4. Radiologically proven progression of disease.
5. Age \> 20 years
6. ECOG PS 0 - 2
7. Life expectancy more than 3 months
8. Adequate organ function for treatment including liver, kidney and bone marrow (absolute neutrophil count (ANC) ≥ 1,500/ul, platelets ≥ 100,000/ul, AST/ALT ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver involvement, Total serum bilirubin ≤ 2.0 mg/dL)
9. Written informed consent

Exclusion Criteria:

1. Prior administration of taxane or anthracycline as palliative chemotherapy. If those agents were used as adjuvant or neoadjuvant aim, at least 6 months should be passed.
2. Uncontrolled medical comorbidities Congestive heart failure (NYHA class III or IV) Recent (within 6 months) unstable angina or myocardial infarct Clinically significant cardiac arrhythmia LVEF \< 45% Liver cirrhosis (Child-Pugh class B or C) Interstitial pneumonia Psychiatric illness/social situations that would limit compliance with study requirements
3. Active CNS metastasis not controllable with radiation or steroid
4. Concurrent administration of systemic chemotherapy or radiotherapy. Palliative radiotherapy for pain control more than 2 weeks ago is acceptable.
5. Pregnant or lactating women.
6. Peripheral neuropathy G3\~4.
7. Metachronous malignancy other than adequately treated CIN of uterine cervix, basal cell or squamous cell carcinoma of the skin.

Primary outcomes:
measure: disease control rate according to the RECIST v1.1
timeFrame: at 6~8 weeks later after the first evaluation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University College of Medicine
Study officials:
References: